NEWS SEARCH ANALYSIS INSIGHT

360° SearchNetwork Hot Spots Trends

Advanced Search Options >>

Sunday, March 21, 2010 3:19 PM

Poniard Pharmaceuticals Inc

Type: Company

Name: Poniard Pharmaceuticals Inc

First Reported Mar 19 2010 - Updated Mar 19 2010 - 1 Documents

USPTO reissues composition of matter patent for Poniard Pharmaceuticals' picoplatin

Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that the U.S. Patent & Trademark Office (USPTO) has granted and will reissue the composition of matter patent for picoplatin ... [Published Mar 19 2010 by News-Medical.Net]

Entities: Poniard Pharmaceuticals Inc, Patent, USPTO

First Reported Mar 15 2010 - Updated Mar 15 2010 - 1 Documents

Poniard Pharmaceuticals Announces $6.3 Million Financing

SOUTH SAN FRANCISCO, Calif., March 15 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced the sale of 4,229,000 of its common shares to Commerce ... [Published Mar 15 2010 by Financial Services]

Entities: Poniard Pharmaceuticals Inc, Oncology, Common Shares

First Reported Mar 12 2010 - Updated Mar 12 2010 - 1 Documents

PARD - Poniard Pharmaceuticals Looking for Approval/Partners

PARD - Poniard Pharmaceuticals which specializes in developing oncology therapies, reported its Fourth Quarter Results at 8:30am today. Their main focus on the call was a cancer fighting drug known as Picoplatin, which is in phase 2 for prostate cancer ... [Published Mar 12 2010 by World Market Media]

Entities: Poniard Pharmaceuticals Inc, small cell lung cancer, Prostate Cancer, Oncology

First Reported Mar 08 2010 - Updated Mar 09 2010 - 3 Documents

Nicox

Lexicon, Poniard weigh on drug stocks

Lexicon Pharmaceuticals was the biggest decliner among the smaller-cap drug stocks Monday, with shares dropping sharply after the company said it plans to sell $95 million of common stock. The shares of the drug developer were down 9% to $1.62 in afternoon ... [Published Mar 09 2010 by MarketWatch]

Entities: Nicox, Food and Drug Administration, Lexicon Pharmaceuticals, Poniard Pharmaceuticals Inc

First Reported Mar 08 2010 - Updated Mar 09 2010 - 1 Documents

Zoom Technologies Incorporated

Dollar Store: Zoom Technologies

YORK (TheStreet) -- Several stocks trading near $5 were moving on above-average volume during Monday's session.Cell Therapeutics (CTIC) jumped by 23 cents, or 26.2%, to $1.13 after the Food and Drug Administration completed an inspection of a facility ... [Published Mar 08 2010 by TheStreet.com]

Entities: Zoom Technologies Incorporated, Robert Holmes, Poniard Pharmaceuticals Inc, International Coal Group Inc

First Reported Mar 08 2010 - Updated Mar 08 2010 - 1 Documents

SmarTrend's Trend Spotter See Continued Downward Momentum on Shares of Poniard Pharmaceuticals (PARD)

Poniard Pharmaceuticals is currently below its 50-day moving average of $1.80 and below its 200-day moving average of $4.91. Look for these moving averages to decline to confirm the company's downward momentum.SmarTrend will continue to scan these moving ... [Published Mar 08 2010 by TradingMarkets]

Entities: Poniard Pharmaceuticals Inc, Spotter, Moving Average

First Reported Mar 08 2010 - Updated Mar 08 2010 - 2 Documents

Poniard Pharmaceuticals reports net loss of $13.2M for fourth-quarter 2009

Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the fourth quarter and year ended December 31, 2009."Picoplatin's value proposition rests on establishing ... [Published Mar 08 2010 by News-Medical.Net]

Entities: Poniard Pharmaceuticals Inc, prednisone, docetaxel

First Reported Mar 07 2010 - Updated Mar 08 2010 - 2 Documents

Poniard reports positive results from Phase II prostate cancer trial

(Datamonitor via COMTEX) --Poniard Pharmaceuticals, a biopharmaceutical company, has reported positive final data, including survival data, from the company's Phase II clinical trial of picoplatin as a first-line therapy in men with metastatic castration-resistant ... [Published Mar 08 2010 by TradingMarkets]

Entities: Prostate Cancer, Poniard Pharmaceuticals Inc, prednisone, docetaxel

First Reported Mar 05 2010 - Updated Mar 06 2010 - 4 Documents

Poniard Pharmaceuticals' picoplatin Phase 2 study in metastatic CRPC: Positive results

Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced the presentation of positive final data, including survival data, from the Company's Phase 2 clinical trial of picoplatin ... [Published Mar 06 2010 by News-Medical.Net]

Entities: Poniard Pharmaceuticals Inc, Metastatic, PHASE 2, Prostate Cancer

First Reported Mar 01 2010 - Updated Mar 01 2010 - 2 Documents

Poniard Pharmaceuticals to Host Fourth Quarter and Year End 2009 Financial Results Conference...

SOUTH SAN FRANCISCO, Calif., March 1 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that it will hold a conference call on Monday, March 8, ... [Published Mar 01 2010 by Forbes.com]

Entities: Poniard Pharmaceuticals Inc, Oncology, South San Francisco (United States), Medical Officer

First Reported Feb 24 2010 - Updated Feb 25 2010 - 3 Documents

Downtrend Spotted in Shares of Poniard Pharmaceuticals (PARD)

Downtrend Spotted in Shares of Poniard Pharmaceuticals (PARD) ... [Published Feb 25 2010 by FOXBusiness.com]

Entities: Poniard Pharmaceuticals Inc

First Reported Feb 23 2010 - Updated Feb 24 2010 - 7 Documents

Poniard Pharmaceuticals, Inc. (PARD) Secures $

SOUTH SAN FRANCISCO, Calif., Feb. 23 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced that it has entered into a committed equity financing facility under which ... [Published Feb 24 2010 by BioSpace]

Entities: Poniard Pharmaceuticals Inc, Common Shares, US Securities and Exchange Commission, Oncology

Quotes

...of strategic opportunities, including potential partnerships," stated Ronald A Martell, chief executive officer of Poniard Pharmaceuticals. "This patent reissue strengthens the intellectual property estate around picoplatin, enhancing its value proposition as a development candidate in a number of cancers, both in its oral and intravenous forms."

USPTO reissues composition of matter patent for Poniard Pharmaceuticals' picoplatin [News-Medical.Net - Mar 19 2010]

'We're starting to be able to see the light at the end of the tunnel,' Scangos said, adding that the latest restructuring will "make sure we have the resources to get us there."

Restructuring Trends Continue in 2010: Exelixis Cuts 270 Jobs [Pharmacy Choice - Mar 10 2010]

"Picoplatin's value proposition rests on establishing it as the preferred platinum," said Ronald A Martell, chief executive officer of Poniard. "With nearly 1,100 patients treated in clinical trials to date, picoplatin has already demonstrated clinically meaningful safety and efficacy in a variety of solid tumor indications as a single agent or in combination. We look forward to finalizing registration strategies in a number of these settings with our clinical advisors and the Food and Drug Administration, while simultaneously evaluating strategic opportunities, including potential partnerships, which we believe will enable us to unlock the full value of picoplatin."

Poniard Pharmaceuticals reports net loss of $13.2M for fourth-quarter 2009 [News-Medical.Net - Mar 08 2010]

More Content

sort by: Date \| Relevance
USPTO reissues composition of matter patent for... [News-Medical.Net - Mar 19 2010]
U.S. Patent and Trademark Office Grants Reissue... [Yahoo! Canada - Mar 18 2010]
Poniard Pharmaceuticals Raises $6.3 Million - Z... [Zibb - Mar 16 2010]
Poniard Pharmaceuticals Raises $6.3 Million [TradingMarkets - Mar 16 2010]
Poniard Pharmaceuticals Announces $6.3 Million ... [Financial Services - Mar 15 2010]
Two Phase 3 studies of Sutent in advanced breas... [News-Medical.Net - Mar 12 2010]
PARD - Poniard Pharmaceuticals Looking for Appr... [World Market Media - Mar 12 2010]
Restructuring Trends Continue in 2010: Exelixis... [Pharmacy Choice - Mar 10 2010]
Monday`s Most Active Losers (PALM, ICO, GMO, IN... [Earthtimes.org - Mar 09 2010]
Lexicon, Poniard weigh on drug stocks [MarketWatch - Mar 09 2010]
MetLife to Acquire AIG's Gem (NYSE: MET, NYSE: ... [World Market Media - Mar 08 2010]
AIG, Cisco, Crown Castle, RF Micro Devices: U.S... [BusinessWeek - Mar 08 2010]
Dollar Store: Zoom Technologies [TheStreet.com - Mar 08 2010]
SmarTrend's Trend Spotter See Continued Downwar... [TradingMarkets - Mar 08 2010]
Biotech Stocks: Lexicon, Poniard lead decliners [MarketWatch - Mar 08 2010]
Poniard Pharmaceuticals reports net loss of $13... [News-Medical.Net - Mar 08 2010]
Lexicon, Poniard lead decliners [MarketWatch - Mar 08 2010]
Poniard Pharmaceuticals, Inc. (PARD) Presents P... [BioSpace - Mar 08 2010]
Poniard Pharmaceuticals, Inc. (PARD) Posts Q4 L... [Street Insider - Mar 08 2010]
Poniard reports positive results from Phase II ... [TradingMarkets - Mar 08 2010]
Poniard Pharma Q4 Loss Narrows - Quick Facts [RTTNews.com - Mar 08 2010]
Poniard Pharmaceuticals Reports Fourth Quarter ... [Financial Services - Mar 08 2010]
Stock Picks For Monday 8 March: THQ, Osiris The... [Daily Markets - Mar 08 2010]
Poniard Pharmaceuticals Presents Positive Survi... [PR-USA.net - Mar 07 2010]
Commodities, Jobs Data Lift ETFs and Stocks (Da... [Smart Money - Mar 07 2010]
Poniard Pharmaceuticals' picoplatin Phase 2 stu... [News-Medical.Net - Mar 06 2010]
Poniard Pharma Reports Positive Final Data From... [RTTNews.com - Mar 05 2010]
Poniard Pharmaceuticals Presents Positive Survi... [Forbes.com - Mar 05 2010]
Poniard Pharmaceuticals Presents Positive Survi... [PR Newswire via MSN Money - Mar 05 2010]
Medivation: Biotech Stock Mailbag [TheStreet.com - Mar 03 2010]

Blogs

sort by: Date \| Relevance
Biophama Firms Lexicon And Poniard In The Hurt ... [24/7 Wall St. - Mar 08 2010] Biophama companies are horrible investments at least 90% of the time because they are gambles on the IQs of small groups of scientists and the whims of the FDA. ...
GlaxoSmithKline, Poniard, Protalix Provide Biot... [Healthcare Sector and Stocks Analysis from Seek ... - Feb 08 2010] The Burrill Report submits: GlaxoSmithKline (GSK) will cut up to 4,000 jobs as the drug giant seeks to cut costs in the face of the loss of revenue from generic ...
GlaxoSmithKline, Poniard, Protalix Provide Biot... [Biotech Sector and Stocks Analysis from Seeking ... - Feb 08 2010] The Burrill Report submits: GlaxoSmithKline (GSK) will cut up to 4,000 jobs as the drug giant seeks to cut costs in the face of the loss of revenue from generic ...
Poniard Pharmaceuticals: A Rebound Is Overdue [Healthcare Sector and Stocks Analysis from Seek ... - Jan 22 2010] M.E. Garza submits: Colorectal cancer is the third most common form of cancer worldwide. Despite significant progress in its treatment over the past decade, colorectal ...
Poniard Pharmaceuticals: A Rebound Is Overdue [Biotech Sector and Stocks Analysis from Seeking ... - Jan 22 2010] M.E. Garza submits: Colorectal cancer is the third most common form of cancer worldwide. Despite significant progress in its treatment over the past decade, colorectal ...